Trump’s ‘gift from God’ drug, espoused by Jewish doctor, does not prevent coronavirus: study
Hydroxychloroquine, the anti-malaria drug that some doctors are using to treat Covid-19. Image by Getty
By Ari Feldman June 4, 2020
Hydroxychloroquine, the anti-malaria drug touted by President Donald Trump as a treatment for Covid-19 — and taken by him to prevent contracting the disease — does not prevent against coronavirus infection when taken prophylactically, a new study found.
The study, published Wednesday in the New England Journal of Medicine, is the first double-blind, placebo-controlled study of the drug, meaning that neither the researchers administering the drug to research subjects, nor the subjects themselves, knew if they were taking hydroxychloroquine or a simple vitamin supplement. That methodology is considered the “gold standard” of medical research.
Dr. Vladimir Zelenko, a Hasidic doctor in New York who has made it his mission to promote the use of hydroxychloroquine to prevent hospitalization by using it to treat high-risk individuals with early symptoms, both criticized the study and touted the fact that it found that the drug is safe overall.
Zelenko’s approach, of prescribing hydroxychloroquine at the earliest signs of Covid-19 symptoms in high-risk individuals, is currently the subject of a controlled study at a hospital on Long Island, which will not release its results until next year.
Zelenko has advised other countries to use the drug prophylactically, however, and said that he took it himself to prevent infection, because he is immunocompromised.
The study’s subjects, who were mailed either the drug or the placebo immediately after being exposed to a Covid-19 patient, were front-line medical workers and first responders. Of the 821 people included in the study’s final results, 88% had high-risk exposures; 12% of the people taking hydroxychloroquine contracted the disease, compared with 14% of those taking the placebo. The study authors concluded that this was not a statistically meaningful difference.
The study did find that the drug, overall, is safe, citing no instances of serious side affects besides nausea and diarrhea. Previous analyses of observational data of hospitalized patients taking the drug found heightened risks of cardiac arrest compared with no use of the drug.
NEJM published misleading study. Only 3% patients had confirmed covid-19. Study managed completely online. Looks like they included many false positives. Study proves that HCQ safe. NO cardiac arrhythmia. TY NEJM. #ZelenkoProtocol @realDonaldTrump @RudyGiuliani @RonJohnsonWI
— Dr Vladimir (Zev) Zelenko (@zev_dr) June 4, 2020
Ari Feldman is a staff writer at the Forward. Contact him at [email protected] or follow him on Twitter @aefeldman
I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning journalism this Passover.
In this age of misinformation, our work is needed like never before. We report on the news that matters most to American Jews, driven by truth, not ideology.
At a time when newsrooms are closing or cutting back, the Forward has removed its paywall. That means for the first time in our 126-year history, Forward journalism is free to everyone, everywhere. With an ongoing war, rising antisemitism, and a flood of disinformation that may affect the upcoming election, we believe that free and open access to Jewish journalism is imperative.
Readers like you make it all possible. Right now, we’re in the middle of our Passover Pledge Drive and we still need 300 people to step up and make a gift to sustain our trustworthy, independent journalism.
Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly.
— Rachel Fishman Feddersen, Publisher and CEO
Join our mission to tell the Jewish story fully and fairly.
Only 300 more gifts needed by April 30
